Program
Docetaxel
Also written as “docetaxel”, “Taxotere” and “HB1801”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 540 open or running | phase 4since Jan 18, 2006 | Nov 1, 1999 | none ahead |
| Hoffmann-La Roche | 220 open or running | phase 4since Aug 5, 2005 | Feb 12, 2004 | none ahead |
| CSPC Pharmaceutical Group | 1511 open or running | phase 3since Apr 20, 2023 | Mar 10, 2021 | Dec 16, 2026phase 3 · NCT06747338 |
| Eli Lilly | 81 open or running | phase 3since Nov 1, 2004 | Nov 1, 2004 | May 2027phase 2 · NCT05999994 |
| Pfizer | 70 open or running | phase 2since Jan 4, 2002 | Jan 4, 2002 | none ahead |
| GlaxoSmithKline | 60 open or running | phase 2since Jul 17, 2003 | Jul 17, 2003 | none ahead |
| Amgen | 40 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Merck | 30 open or running | phase 2since Oct 4, 2007 | Oct 4, 2007 | none ahead |
| novacea | 30 open or running | phase 3since Aug 9, 2002 | Aug 9, 2002 | none ahead |
| Novartis | 20 open or running | phase 3since Jun 29, 2004 | Jun 29, 2004 | none ahead |
| Samyang Biopharmaceuticals | 20 open or running | phase 1since Mar 21, 2011 | Mar 21, 2011 | none ahead |
| academy-military-medical-science-china | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 1since Nov 23, 2009 | Nov 23, 2009 | none ahead |
| healthcare-global-enterprise-ltd | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| hope-cancer-institute-inc | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Ionis Pharmaceuticals | 10 open or running | phase 2since Nov 2, 2010 | Nov 2, 2010 | none ahead |
| lidds-ab | 10 open or running | phase 1since Mar 18, 2021 | Mar 18, 2021 | none ahead |
| nanology-llc | 10 open or running | phase 1since Feb 5, 2020 | Feb 5, 2020 | none ahead |
| oshadi-drug-administration | 10 open or running | phase 2since May 7, 2014 | May 7, 2014 | none ahead |
| relmada-therapeutics-inc | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| shanghai-miracogen-inc | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Simcere Pharmaceutical Group | 10 open or running | phase 1since May 25, 2020 | May 25, 2020 | none ahead |
| Sumitomo Pharma | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| Swedish Orphan Biovitrum | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| zhuhai-beihai-biotech-co-ltd | 11 open or running | phase 2since Dec 9, 2024 | Dec 9, 2024 | none ahead |
| zivena | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: parexel, jazz-pharmaceuticals-ireland-limited, baili-bio-chengdu-pharmaceutical-co-ltd, clovis-oncology-inc, Astellas Pharma, Exelixis, Gilead Sciences, iteos-belgium-sa, intas-pharmaceuticals-ltd, lambda-therapeutic-research-ltd, medigen-biotechnology-corporation, us-biotest-inc, quintiles-inc, mds-pharma-services, AstraZeneca and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 13, 2008.
- Feb 22, 2023shanghai-miracogen-inc's first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
- Apr 20, 2023Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT05838066 · 880 planned · China
- May 8, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT05863325 · 80 planned · China
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- Feb 28, 2024Phase 3 study in Stomach NeoplasmsCSPC Pharmaceutical Group · NCT06296706 · 630 planned · China
- Mar 13, 2024Phase 3 study in Squamous Cell Non-small Cell Lung CancerCSPC Pharmaceutical Group · NCT06319313 · 534 planned
- Jun 24, 2024Phase 3 study in Advanced Pancreatic CancerCSPC Pharmaceutical Group · NCT06492941 · 142 planned
- Aug 8, 2024relmada-therapeutics-inc's first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to relmada-therapeutics-increlmada-therapeutics-inc · NCT06663137 · 70 planned · Israel
- Dec 9, 2024zhuhai-beihai-biotech-co-ltd's first study: phase 2 study in Urinary Bladder NeoplasmsNew to zhuhai-beihai-biotech-co-ltdzhuhai-beihai-biotech-co-ltd · NCT06732531 · 48 planned · China
- Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338 · 520 enrolled · China
- Jul 15, 2025Phase 2 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT07083505 · 60 planned
- Aug 7, 2025Phase 2 study in HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07116824 · 80 planned
- Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07441460 · 1,800 planned · China
- Aug 28, 2026Phase 3 study in HER2-Negative Advanced Breast CancerCSPC Pharmaceutical Group · NCT07805135 · 430 planned
Ahead
- Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
- Nov 2027Primary completion: phase 2 study in Non-Muscle Invasive Bladder Neoplasmsrelmada-therapeutics-inc · NCT06663137
- Jun 1, 2028Primary completion: phase 3 study in HER2-Negative Advanced Breast CancerCSPC Pharmaceutical Group · NCT07805135
TargetBeta
“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
The newest 60 of 142 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07805135HER2-Negative Advanced Breast Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 1, 2028 | 430 |
| NCT07441460Resectable HER2-positive Breast Cancer · China | 3 | Recruiting | CSPC Pharmaceutical Group | Aug 7, 2034 | 1,800 |
| NCT07116824HER2-positive Breast Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 15, 2026 | 80 |
| NCT07083505Advanced Breast Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 11, 2026 | 60 |
| NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China | 3 | Active, not recruiting | CSPC Pharmaceutical Group | Dec 16, 2026 | 520 |
| NCT06732531Urinary Bladder Neoplasms · China | 2 | Recruiting | zhuhai-beihai-biotech-co-ltd | Dec 2025 | 48 |
| NCT06663137Non-Muscle Invasive Bladder Neoplasms · Israel | 2 | Recruiting | relmada-therapeutics-inc | Nov 2027 | 70 |
| NCT06492941Advanced Pancreatic Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 14, 2026 | 142 |
| NCT06319313Squamous Cell Non-small Cell Lung Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 1, 2026 | 534 |
| NCT06296706Stomach Neoplasms · China | 3 | Recruiting | CSPC Pharmaceutical Group | Jun 1, 2026 | 630 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05863325Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | CSPC Pharmaceutical Group | Mar 2024 | 80 |
| NCT05838066Breast Neoplasms · China | 3 | Recruiting | CSPC Pharmaceutical Group | Jul 31, 2025 | 880 |
| NCT05754853Advanced or Metastatic Urothelium Cancer · China | 3 | Recruiting | shanghai-miracogen-inc | Oct 2025 | 290 |
| NCT05705635Gastric Adenocarcinoma · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | May 2023 | 100 |
| NCT05616494Pancreatic Neoplasms · China | 2 | Recruiting | CSPC Pharmaceutical Group | Dec 31, 2024 | 53 |
| NCT05325229Platinum-resistant Recurrent Ovarian Cancer · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 2024 | 94 |
| NCT05027204Squamous Cell Carcinoma of Head and Neck · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Oct 31, 2023 | 94 |
| NCT04810208Solid Tumor · Denmark, Lithuania, Sweden | 1 | Terminated | lidds-ab | Oct 7, 2021 | 6 |
| NCT04811118Advanced Solid Tumors · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Oct 31, 2022 | 27 |
| NCT04725188Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Completed | Merck | Jan 26, 2023 | 255 |
| NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States | 1 | Completed | Sumitomo Pharma | May 28, 2024 | 48 |
| NCT04471428Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Sep 28, 2022 | 366 |
| NCT04413227NSCLC · China | 1 | UNKNOWN | Simcere Pharmaceutical Group | May 31, 2021 | 30 |
| NCT04404140Prostatic Neoplasms, Castration-Resistant · France, Italy, Spain and more | 1 | Terminated | Hoffmann-La Roche | Oct 14, 2022 | 6 |
| NCT04260360Carcinoma, Renal Cell | 1 | Withdrawn | nanology-llc | Jun 2022 | 0 |
| NCT03739710Neoplasms · United States, Canada, France and more | 2 | Completed | GlaxoSmithKline | May 2, 2024 | 175 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT02985255Tongue Neoplasms · India | 2 | UNKNOWN | healthcare-global-enterprise-ltd | Jun 2017 | 30 |
| NCT02831491Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Eli Lilly | Jul 2017 | 0 |
| NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more | 2 | Completed | Hoffmann-La Roche | Mar 2006 | 225 |
| NCT02605915Breast Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Nov 13, 2019 | 98 |
| NCT02445586Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Sep 26, 2018 | 52 |
| NCT02419742Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Jun 24, 2021 | 110 |
| NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more | 3 | Completed | Hoffmann-La Roche | Feb 22, 2019 | 418 |
| NCT02274610Solid Tumor | 1 | Completed | Samyang Biopharmaceuticals | Nov 2015 | 18 |
| NCT02134990Carcinoma, Non-Small-Cell Lung · Israel | 2 | UNKNOWN | oshadi-drug-administration | Jan 2019 | 20 |
| NCT02005549Breast Neoplasms · Austria | 2 | Completed | Hoffmann-La Roche | Apr 2008 | 18 |
| NCT01938456Carcinoma, Non-Small-Cell Lung | 1 | Withdrawn | GlaxoSmithKline | Jul 2014 | 0 |
| NCT01862081Breast Neoplasms · United States, Belgium, Canada and more | 1 | Completed | Hoffmann-La Roche | Jun 9, 2017 | 80 |
| NCT01718353Prostate Cancer Metastatic · United States, Canada | 2 | Completed | Sanofi | Aug 2015 | 63 |
| NCT01515748Stomach Neoplasms · Korea, Republic of | 3 | Completed | Sanofi | Jan 21, 2019 | 530 |
| NCT01336582Solid Tumor · Korea, Republic of | 1 | Completed | Samyang Biopharmaceuticals | Apr 2012 | 42 |
| NCT01266512Lung Neoplasms · Hong Kong | 2 | Completed | Sanofi | Mar 2014 | 34 |
| NCT01234025Castrate-Resistant Prostate Cancer · United States, Hungary, Poland and more | 2 | Completed | Ionis Pharmaceuticals | May 2013 | 113 |
| NCT01220128Breast Neoplasms · United States, Belgium, France and more | 2 | Terminated | GlaxoSmithKline | Nov 14, 2014 | 66 |
| NCT01148615Neoplasms · China | 1 | Completed | Sanofi | Sep 2011 | 20 |
| NCT01038661Lung Neoplasms · China | 3 | Completed | Sanofi | Aug 2012 | 375 |
| NCT01019941Advanced Solid Cancers · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Aug 2010 | 44 |
| NCT00964704Breast Neoplasms | 2 | Withdrawn | Hoffmann-La Roche | Aug 2013 | 0 |
| NCT00934856Breast Neoplasms · United States, France, Spain and more | 2 | Completed | Hoffmann-La Roche | Oct 2013 | 98 |
| NCT00927589Solid Cancers · United States | 1 | Completed | Hoffmann-La Roche | Feb 2013 | 59 |
| NCT00916097Head and Neck Neoplasms · Algeria, Morocco, Tunisia | 2 | Completed | Sanofi | Nov 2005 | 66 |
| NCT00845910Breast Neoplasms · Taiwan | 2 | Terminated | Hoffmann-La Roche | May 2011 | 22 |
| NCT00819728Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Sanofi | 35 | |
| NCT00816543Stomach Neoplasms · Korea, Republic of | 2 | Completed | Sanofi | May 2012 | 41 |
| NCT00811447Stomach Neoplasms · China | 3 | Completed | Sanofi | Jun 2012 | 243 |
| NCT00774241Breast Neoplasms | 4 | Withdrawn | Hoffmann-La Roche | Nov 2013 | 0 |
| NCT00773695Breast Neoplasms · Norway | 2 | Completed | Hoffmann-La Roche | Nov 9, 2022 | 150 |
| NCT00826852Lung Neoplasms · Turkey | 2 | Completed | Sanofi | Jul 2009 | 49 |
How it is read
Names in the registry
- “Docetaxel”, 93 entries
- “docetaxel”, 37 entries
- “Taxotere”, 9 entries
- “HB1801”, 8 entries
- “Docetaxel for injection (Albumin-bound)”, 4 entries
Codes read as this program: CKD810.
Conditions, from the studies’ own filings
- Breast Neoplasms, 54 studies
- Carcinoma, Non-Small-Cell Lung, 48 studies
- Prostatic Neoplasms, 21 studies
- Stomach Neoplasms, 9 studies
- Lung Neoplasms, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.